Last reviewed · How we verify

Peg-IFN + LD RBV for 24 weeks — Competitive Intelligence Brief

Peg-IFN + LD RBV for 24 weeks (Peg-IFN + LD RBV for 24 weeks) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Virology/Hepatology.

marketed Antiviral combination therapy Interferon alpha receptor; HCV RNA-dependent RNA polymerase Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Peg-IFN + LD RBV for 24 weeks (Peg-IFN + LD RBV for 24 weeks) — National Taiwan University Hospital. Pegylated interferon alpha combined with low-dose ribavirin stimulates the immune system to suppress hepatitis C virus replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Peg-IFN + LD RBV for 24 weeks TARGET Peg-IFN + LD RBV for 24 weeks National Taiwan University Hospital marketed Antiviral combination therapy Interferon alpha receptor; HCV RNA-dependent RNA polymerase
Peg interferon + Ribavirin Peg interferon + Ribavirin University of Valencia marketed Antiviral combination therapy Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase
Peg-IFN + RBV Peg-IFN + RBV National Taiwan University Hospital marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Xenical, Pegasys, Copegus Xenical, Pegasys, Copegus Brooke Army Medical Center marketed Antiviral combination therapy (interferon + nucleoside analog); Lipase inhibitor Hepatitis C virus NS5B polymerase; pancreatic lipase
Ganovo+ritonavir+/-Interferon nebulization Ganovo+ritonavir+/-Interferon nebulization The Ninth Hospital of Nanchang marketed Antiviral combination therapy Viral RNA-dependent RNA polymerase; CYP3A4 (ritonavir); Interferon-alpha/beta receptors
D: Peg-interferon alpha-2a & Ribavirin D: Peg-interferon alpha-2a & Ribavirin Kaohsiung Medical University Chung-Ho Memorial Hospital marketed Antiviral combination therapy Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
F: Peg-interferon alpha-2a & Ribavirin F: Peg-interferon alpha-2a & Ribavirin Kaohsiung Medical University Chung-Ho Memorial Hospital marketed Antiviral combination therapy Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

  1. Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
  2. National Taiwan University Hospital · 6 drugs in this class
  3. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
  4. Hepatitis Resource Network · 1 drug in this class
  5. Hospices Civils de Lyon · 1 drug in this class
  6. MTI Medical Private Limited, Pakistan · 1 drug in this class
  7. Pacific Health Foundation · 1 drug in this class
  8. RedHill Biopharma Limited · 1 drug in this class
  9. Sherief Abd-Elsalam · 1 drug in this class
  10. The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peg-IFN + LD RBV for 24 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-ifn-ld-rbv-for-24-weeks. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: